Big Pharma Is Buying — Why Biotech Stocks Could Outperform in 2026

Biotech is quietly stepping into a leadership role here in early 2026 — and the move is not happening in a vacuum.After years of underperformance from 2021 through much of 2024, the sector began a powerful rebound in the second half of 2025.  That rally was significant. From its April 2025 lows, the SPDR S&P Biotech ETF (NASDAQ: IBB) surged roughly 75%, dramatically outperforming the broader market’s move over the same period.In many ways, that outperformance looked like a long-overdue catch-up trade.  ...